In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from neuroimaging research in humans and rodent models

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 4, 2010, Pages 373-388

  Higuchi, Makoto ^a   Maeda, Jun ^a   Ji, Bin ^a   Maruyama, Masahiro ^a   Okauchi, Takashi ^a   Tokunaga, Masaki ^a   Ono, Maiko ^a   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Dementia; Mouse model; Neurodegeneration; Positron emission tomography

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; AMYLOIDOSIS; BRAIN ELECTROPHYSIOLOGY; CALCIUM HOMEOSTASIS; DEGENERATIVE DISEASE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENETIC MANIPULATION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMAGE ANALYSIS; IN VIVO STUDY; MOLECULAR INTERACTION; MUTAGENESIS; NEUROIMAGING; NEUROIMMUNOLOGY; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TAUOPATHY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RODENTIA; TAU PROTEINS;

ANIMALIA; RODENTIA;

EID: 76749104184     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.01.003     Document Type: Review

References (221)

1. Walker L.C., and Cork L.C. The neurobiology of aging in nonhuman primates. In: Terry R.D., Katzman R., Bick K.L., and Sisodia S.S. (Eds). Alzheimer Disease. 2nd Edition (1999), Lippincott Williams & Wilkins, Philadelphia 233-243
2. Rosen R.F., Farberg A.S., Gearing M., Dooyema J., Long P.M., Anderson D.C., Davis-Turak J., Coppola G., Geschwind D.H., Pare J.F., Duong T.Q., Hopkins W.D., Preuss T.M., and Walker L.C. Tauopathy with paired helical filaments in an aged chimpanzee. J. Comp. Neurol. 509 (2008) 259-270
3. Schwab C., Hosokawa M., and McGeer P.L. Transgenic mice overexpressing amyloid β protein are an incomplete model of Alzheimer disease. Exp. Neurol. 188 (2004) 52-64
4. Howlett D.R., and Richardson J.C. The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP?. Histol. Histopathol. 24 (2009) 83-100
5. Forman M.S., Trojanowski J.Q., and Lee V.M.Y. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 10 (2004) 1055-1063
6. Chartier-Harlin M.C., Crawford F., Houlden H., Warren A., Hughes D., Fidani L., Goate A., Rossor M., Roques P., Hardy J., and Mullan M. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 353 (1991) 844-846
7. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C., Pericak-Vance M., Roses A., Williamson R., Rossor M., Owen M., and Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 (1991) 704-706
8. Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., Liang Y., Chi H., Lin C., Holman K., Tsuda T., Mar L., Sorbi S., Nacmias B., Piacentini S., Amaducci L., Chumakov I., Cohen D., Lannfelt L., Fraser P.E., Rommens J.M., and St George-Hyslop P.H. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376 (1995) 775-778
9. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., Yu C.E., Jondro P.D., Schmidt S.D., Wang K., Crowley A.C., Fu Y.H., Guenette S.Y., Galas D., Nemens E., Wijsman E.M., Bird T.D., Schellenberg G.D., and Tanzi R.E. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269 (1995) 973-977
10. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K., Tsuda T., Mar L., Foncin J.F., Bruni A.C., Montesi M.P., Sorbi S., Rainero I., Pinessi L., Nee L., Chumakov I., Pollen D., Brookes A., Sanseau P., Polinsky R.J., Wasco W., Da Silva H.A.R., Haines J.L., Pericak-Vance M.A., Tanzi R.E., Roses A.D., Fraser P.E., Rommens J.M., and St George-Hyslop P.H. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 (1995) 754-760
11. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J.M., Nowotny P., Che L.K., Norton J., Morris J.C., Reed L.A., Trojanowski J., Basun H., Lannfelt L., Neystat M., Fahn S., Dark F., Tannenberg T., Dodd P.R., Hayward N., Kwok J.B., Schofield P.R., Andreadis A., Snowden J., Craufurd D., Neary D., Owen F., Oostra B.A., Hardy J., Goate A., van Swieten J., Mann D., Lynch T., and Heutink P. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393 (1998) 702-705
12. Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., Andreadis A., Wiederholt W.C., Raskind M., and Schellenberg G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43 (1998) 815-825
13. Spillantini M.G., Murrell J.R., Goedert M., Farlow M.R., Klug A., and Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 7737-7741
14. Higuchi M., Lee V.M.Y., and Trojanowski J.Q. Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med. 2 (2002) 131-150
15. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
16. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
17. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Bürki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., and Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13287-13292
18. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., and Younkin S. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 383 (1996) 710-713
19. Götz J., Streffer J.R., David D., Schild A., Hoerndli F., Pennanen L., Kurosinski P., and Chen F. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol. Psychiatry 9 (2004) 664-683
20. Ishihara T., Hong M., Zhang B., Nakagawa Y., Lee M.K., Trojanowski J.Q., and Lee V.M.Y. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24 (1999) 751-762
21. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., and Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25 (2000) 402-405
22. Higuchi M., Ishihara T., Zhang B., Hong M., Andreadis A., Trojanowski J.Q., and Lee V.M.Y. Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration. Neuron 35 (2002) 433-446
23. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., and Ashe K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (2005) 476-481
24. Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., and Lee V.M.Y. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53 (2007) 337-351
25. Götz J., and Ittner L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 9 (2008) 532-544
26. Serdons K., Verbruggen A., and Bormans G.M. Developing new molecular imaging probes for PET. Methods 48 (2009) 104-111
27. 11C]WAY-100635: effects of depression and antidepressant treatment. Arch. Gen. Psychiatry 57 (2000) 174-180
28. 18F]MPPF binding potential in the dorsal raphe nucleus after a single oral dose of fluoxetine: a positron-emission tomography study in healthy volunteers. Biol. Psychiatry 63 (2008) 1135-1140
29. Sunde M., Serpell L.C., Bartlam M., Fraser P.E., Pepys M.B., and Blake C.C.F. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol. 273 (1997) 729-739
30. Fändrich M., and Dobson C.M. The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation. EMBO J. 21 (2002) 5682-5690
31. Krebs M.R., Bromley E.H., and Donald A.M. The binding of thioflavin-T to amyloid fibrils: localisation and implications. J. Struct. Biol. 149 (2005) 30-37
32. Kung H.F., Lee C.W., Zhuang Z.P., Kung M.P., Hou C., and Plössl K. Novel stilbenes as probes for amyloid plaques. J. Am. Chem. Soc. 123 (2001) 12740-12741
33. Sair H.I., Doraiswamy P.M., and Petrella J.R. In vivo amyloid imaging in Alzheimer's disease. Neuroradiology 46 (2004) 93-104
34. Mathis C.A., Bacskai B.J., Kajdasz S.T., McLellan M.E., Frosch M.P., Hyman B.T., Holt D.P., Wang Y., Huang G.F., Debnath M.L., and Klunk W.E. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg. Med. Chem. Lett. 12 (2002) 295-298
35. Okamura N., Suemoto T., Furumoto S., Suzuki M., Shimadzu H., Akatsu H., Yamamoto T., Fujiwara H., Nemoto M., Maruyama M., Arai H., Yanai K., Sawada T., and Kudo Y. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J. Neurosci. 25 (2005) 10857-10862
36. Crystal A.S., Giasson B.I., Crowe A., Kung M.P., Zhuang Z.P., Trojanowski J.Q., and Lee V.M.Y. A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J. Neurochem. 86 (2003) 1359-1368
37. Fodero-Tavoletti M.T., Mulligan R.S., Okamura N., Furumoto S., Rowe C.C., Kudo Y., Masters C.L., Cappai R., Yanai K., and Villemagne V.L. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. Eur. J. Pharmacol. 617 (2009) 54-58
38. Ye L., Velasco A., Fraser G., Beach T.G., Sue L., Osredkar T., Libri V., Spillantini M.G., Goedert M., and Lockhart A. In vitro high affinity α-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J. Neurochem. 105 (2008) 1428-1437
39. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 46 (2003) 2740-2754
40. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., Read S., Satyamurthy N., Petric A., Huang S.C., and Barrio J.R. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 10 (2002) 24-35
41. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., and Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55 (2004) 306-319
42. Kudo Y., Okamura N., Furumoto S., Tashiro M., Furukawa K., Maruyama M., Itoh M., Iwata R., Yanai K., and Arai H. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J. Nucl. Med. 48 (2007) 553-561
43. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7 (2008) 129-135
44. 11C]AZD2184. Eur. J. Nucl. Med. Mol. Imaging 36 (2009) 1859-1863
45. Klunk W.E., Wang Y., Huang G.F., Debnath M.L., Holt D.P., Shao L., Hamilton R.L., Ikonomovic M.D., DeKosky S.T., and Mathis C.A. The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J. Neurosci. 23 (2003) 2086-2092
46. Fodero-Tavoletti M.T., Smith D.P., McLean C.A., Adlard P.A., Barnham K.J., Foster L.E., Leone L., Perez K., Cortés M., Culvenor J.G., Li Q.X., Laughton K.M., Rowe C.C., Masters C.L., Cappai R., and Villemagne V.L. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J. Neurosci. 27 (2007) 10365-10371
47. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., Lopresti B.J., Ziolko S., Bi W., Paljug W.R., Debnath M.L., Hope C.E., Isanski B.A., Hamilton R.L., and DeKosky S.T. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131 (2008) 1630-1645
48. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.F., Shao L., DeKosky S.T., Price J.C., and Mathis C.A. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 25 (2005) 10598-10606
49. 11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 32 (2005) 593-600
50. Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., Staufenbiel M., Iwata N., Ono M., Saido T.C., Suzuki K., Mori H., Higuchi M., and Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 27 (2007) 10957-10968
51. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., and Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4 (1998) 97-100
52. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., and Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21 (2001) 372-381
53. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., and LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39 (2003) 409-421
54. Rosen R.F., Walker L.C., and Levine III H. PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease. Neurobiol. Aging (Mar 27, 2009) (online publication ahead of print)
55. Saido T.C., Iwatsubo T., Mann D.M., Shimada H., Ihara Y., and Kawashima S. Dominant and differential deposition of distinct β-amyloid peptide species, A β N3(pE), in senile plaques. Neuron 14 (1995) 457-466
56. Iwatsubo T., Saido T.C., Mann D.M., Lee V.M., and Trojanowski J.Q. Full-length amyloid-β (1-42(43)) and amino-terminally modified and truncated amyloid-β 42(43) deposit in diffuse plaques. Am. J. Pathol. 149 (1996) 1823-1830
57. Frenkel D., Dewachter I., Van Leuven F., and Solomon B. Reduction of β-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. Vaccine 21 (2003) 1060-1065
58. Solomon B. Alzheimer's disease immunotherapy: from in vitro amyloid immunomodulation to in vivo vaccination. J. Alzheimers Dis. 9 (2006) 433-438
59. Gardberg A.S., Dice L.T., Ou S., Rich R.L., Helmbrecht E., Ko J., Wetzel R., Myszka D.G., Patterson P.H., and Dealwis C. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 15659-15664
60. Steinitz M. Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease. Expert Opin. Biol. Ther. 8 (2008) 633-642
61. Lee M., Bard F., Johnson-Wood K., Lee C., Hu K., Griffith S.G., Black R.S., Schenk D., and Seubert P. Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies. Ann. Neurol. 58 (2005) 430-435
62. Petkova1 A.T., Yau W.M., and Tycko R. Experimental constraints on quaternary structure in Alzheimer's β-amyloid fibrils. Biochemistry 45 (2006) 498-512
63. Güntert A., Döbeli H., and Bohrmann B. High sensitivity analysis of amyloid-β peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143 (2006) 461-475
64. Iwata N., Tsubuki S., Takaki Y., Watanabe K., Sekiguchi M., Hosoki E., Kawashima-Morishima M., Lee H.J., Hama E., Sekine-Aizawa Y., and Saido T.C. Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6 (2000) 143-150
65. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., Gerard C., Hama E., Lee H.J., and Saido T.C. Metabolic regulation of brain Aβ by neprilysin. Science 292 (2001) 1550-1552
66. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., and Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4162-4167
67. Schilling S., Hoffmann T., Manhart S., Hoffmann M., and Demuth H.U. Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett. 563 (2004) 191-196
68. Cynis H., Schilling S., Bodnár M., Hoffmann T., Heiser U., Saido T.C., and Demuth H.U. Inhibition of glutaminyl cyclase alters pE formation in mammalian cells. Biochim. Biophys. Acta 1764 (2006) 1618-1625
69. Schilling S., Zeitschel U., Hoffmann T., Heiser U., Francke M., Kehlen A., Holzer M., Hutter-Paier B., Prokesch M., Windisch M., Jagla W., Schlenzig D., Lindner C., Rudolph T., Reuter G., Cynis H., Montag D., Demuth H.U., and Rossner S. Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease-like pathology. Nat. Med. 14 (2008) 1106-1111
70. He W., and Barrow C.J. The Aβ 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater β-sheet forming and aggregation propensities in vitro than full-length Aβ. Biochemistry 38 (1999) 10871-10877
71. Schilling S., Lauber T., Schaupp M., Manhart S., Scheel E., Böhm G., and Demuth H.U. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 45 (2006) 12393-12399
72. Russo C., Violani E., Salis S., Venezia V., Dolcini V., Damonte G., Benatti U., D'Arrigo C., Patrone E., Carlo P., and Schettini G. Pyroglutamate-modified amyloid β-peptides-AβN3(pE)-strongly affect cultured neuron and astrocyte survival. J. Neurochem. 82 (2002) 1480-1489
73. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67 (2006) 446-452
74. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., Mathis C.A., Klunk W.E., Masters C.L., and Rowe C.C. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130 (2007) 2837-2844
75. Jack Jr. C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., Weiner M., Petersen R.C., and Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132 (2009) 1355-1365
76. Price J.L., McKeel Jr. D.W., Buckles V.D., Roe C.M., Xiong C., Grundman M., Hansen L.A., Petersen R.C., Parisi J.E., Dickson D.W., Smith C.D., Davis D.G., Schmitt F.A., Markesbery W.R., Kaye J., Kurlan R., Hulette C., Kurland B.F., Higdon R., Kukull W., and Morris J.C. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 30 (2009) 1026-1036
77. Iwata N., Takaki Y., Fukami S., Tsubuki S., and Saido T.C. Region-specific reduction of A β-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J. Neurosci. Res. 70 (2002) 493-500
78. Russo R., Borghi R., Markesbery W., Tabaton M., and Piccini A. Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. FEBS Lett. 579 (2005) 6027-6030
79. Hellström-Lindahl E., Ravid R., and Nordberg A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A β levels. Neurobiol. Aging 29 (2008) 210-221
80. Xiao Z.M., Sun L., Liu Y.M., Zhang J.J., and Huang J. Estrogen regulation of the neprilysin gene through a hormone-responsive element. J. Mol. Neurosci. 39 (2009) 22-26
81. Saito T., Iwata N., Tsubuki S., Takaki Y., Takano J., Huang S.M., Suemoto T., Higuchi M., and Saido T.C. Somatostatin regulates brain amyloid beta peptide Aβ42 through modulation of proteolytic degradation. Nat. Med. 11 (2005) 434-439
82. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., and Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42 (1992) 631-639
83. Bierer L.M., Hof P.R., Purohit D.P., Carlin L., Schmeidler J., Davis K.L., and Perl D.P. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch. Neurol. 52 (1995) 81-88
84. Wischik C.M., Novak M., Edwards P.C., Klug A., Tichelaar W., and Crowther R.A. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 4884-4888
85. Berriman J., Serpell L.C., Oberg K.A., Fink A.L., Goedert M., and Crowther R.A. Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-β structure. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9034-9038
86. Velasco A., Fraser G., Delobel P., Ghetti B., Lavenir I., and Goedert M. Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans, trans)-1-fluoro-2, 5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene]. FEBS Lett. 582 (2008) 901-906
87. Higuchi M. Visualization of brain amyloid and microglial activation in mouse models of Alzheimer's disease. Curr. Alzheimer. Res. 6 (2009) 137-143
88. Zhuang Z.P., Kung M.P., Hou C., Skovronsky D.M., Gur T.L., Plössl K., Trojanowski J.Q., Lee V.M.Y., and Kung H.F. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J. Med. Chem. 44 (2001) 1905-1914
89. Agdeppa E.D., Kepe V., Liu J., Flores-Torres S., Satyamurthy N., Petric A., Cole G.M., Small G.W., Huang S.C., and Barrio J.R. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer's disease. J. Neurosci. 21 (2001) RC189
90. Small G.W., Kepe V., Ercoli L.M., Siddarth P., Bookheimer S.Y., Miller K.J., Lavretsky H., Burggren A.C., Cole G.M., Vinters H.V., Thompson P.M., Huang S.C., Satyamurthy N., Phelps M.E., and Barrio J.R. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 355 (2006) 2652-2663
91. Schmidt M.L., Schuck T., Sheridan S., Kung M.P., Kung H., Zhuang Z.P., Bergeron C., Lamarche J.S., Skovronsky D., Giasson B.I., Lee V.M., and Trojanowski J.Q. The fluorescent Congo red derivative, (trans, trans)-1-bromo-2, 5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains. Am. J. Pathol. 159 (2001) 937-943
92. Ihara Y., Nukina N., Miura R., and Ogawara M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J. Biochem. 99 (1986) 1807-1810
93. Ksiezak-Reding H., Dickson D.W., Davies P., and Yen S.H. Recognition of tau epitopes by anti-neurofilament antibodies that bind to Alzheimer neurofibrillary tangles. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 3410-3414
94. Lee V.M., Balin B.J., Otvos Jr. L., and Trojanowski J.Q. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251 (1991) 675-678
95. Bhat R.V., Budd Haeberlein S.L., and Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem. 89 (2004) 1313-1317
96. Drechsel D.N., Hyman A.A., Cobb M.H., and Kirschner M.W. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 3 (1992) 1141-1154
97. Biernat J., Gustke N., Drewes G., Mandelkow E.M., and Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immuno-reactivity and microtubule binding. Neuron 11 (1993) 153-163
98. Bramblett G.T., Goedert M., Jakes R., Merrick S.E., Trojanowski J.Q., and Lee Abnormal V.M.Y. tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 10 (1993) 1089-1099
99. Mandelkow E.M., Drewes G., Biernat J., Gustke N., Van Lint J., Vandenheede J.R., and Mandelkow E. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett. 314 (1992) 315-321
100. Baumann K., Mandelkow E.M., Biernat J., Piwnica-Worms H., and Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 336 (1993) 417-424
101. Kobayashi S., Ishiguro K., Omori A., Takamatsu M., Arioka M., Imahori K., and Uchida T. A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline directed protein kinase associated with microtubule. FEBS Lett. 335 (1993) 171-175
102. Drewes G., Lichtenberg-Kraag B., Döring F., Mandelkow E.M., Biernat J., Goris J., Dorée M., and Mandelkow E. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J. 11 (1992) 2131-2138
103. Goedert M., Cohen E.S., Jakes R., and Cohen P. p42 MAP kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease. FEBS Lett. 312 (1992) 95-99
104. Chirita C., Necula M., and Kuret J. Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43 (2004) 2879-2887
105. Necula M., Chirita C.N., and Kuret J. Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry 44 (2005) 10227-10237
106. Pickhardt M., Gazova Z., von Bergen M., Khlistunova I., Wang Y., Hascher A., Mandelkow E.M., Biernat J., and Mandelkow E. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J. Biol. Chem. 280 (2005) 3628-3635
107. Taniguchi S., Suzuki N., Masuda M., Hisanaga S., Iwatsubo T., Goedert M., and Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280 (2005) 7614-7623
108. Masuda M., Suzuki N., Taniguchi S., Oikawa T., Nonaka T., Iwatsubo T., Hisanaga S., Goedert M., and Hasegawa M. Small molecule inhibitors of α-synuclein filament assembly. Biochemistry 45 (2006) 6085-6094
109. Pickhardt M., Larbig G., Khlistunova I., Coksezen A., Meyer B., Mandelkow E.M., Schmidt B., and Mandelkow E. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 46 (2007) 10016-10023
110. Bulic B., Pickhardt M., Schmidt B., Mandelkow E.M., Waldmann H., and Mandelkow E. Development of tau aggregation inhibitors for Alzheimer's disease. Angew. Chem. Int. Ed. Engl. 48 (2009) 1740-1752
111. Gestwicki J.E., Crabtree G.R., and Graef I.A. Harnessing chaperones to generate small-molecule inhibitors of amyloid β aggregation. Science 306 (2004) 865-869
112. Lorenzo A., and Yankner B.A. β-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 12243-12247
113. Ishikawa K., Doh-ura K., Kudo Y., Nishida N., Murakami-Kubo I., Ando Y., Sawada T., and Iwaki T. Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies. J. Gen. Virol. 85 (2004) 1785-1790
114. Ye L., Morgenstern J.L., Gee A.D., Hong G., Brown J., and Lockhart A. Delineation of positron emission tomography imaging agent binding sites on β-amyloid peptide fibrils. J. Biol. Chem. 280 (2005) 23599-23604
115. Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M., Axelman K., Forsell C., Stenh C., Luthman J., Teplow D.B., Younkin S.G., Näslund J., and Lannfelt L. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat. Neurosci. 4 (2001) 887-893
116. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
117. Lesné S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
118. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., and Selkoe D.J. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14 (2008) 837-842
119. Weksler M.E., Gouras G., Relkin N.R., and Szabo P. The immune system, amyloid-β peptide, and Alzheimer's disease. Immunol. Rev. 205 (2005) 244-256
120. Eikelenboom P., Veerhuis R., Scheper W., Rozemuller A.J., van Gool W.A., and Hoozemans J.J. The significance of neuroinflammation in understanding Alzheimer's disease. J. Neural Transm. 113 (2006) 1685-1695
121. Weiner H.L., and Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol. 6 (2006) 404-416
122. Block M.L., Zecca L., and Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8 (2007) 57-69
123. Maccioni R.B., Rojo L.E., Fernández J.A., and Kuljis R.O. The role of neuroimmunomodulation in Alzheimer's disease. Ann. N. Y. Acad. Sci. 1153 (2009) 240-246
124. Salmina A.B. Neuron-glia interactions as therapeutic targets in neurodegeneration. J. Alzheimers Dis. 16 (2009) 485-502
125. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
126. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., and Westaway D. A β peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
127. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., and Arendash G.W. A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
128. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., and Yednock T. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 (2000) 916-919
129. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8850-8855
130. Noble W., Garwood C., Stephenson J., Kinsey A.M., Hanger D.P., and Anderton B.H. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J. 23 (2009) 739-750
131. Zilka N., Ferencik M., and Hulin I. Neuroinflammation in Alzheimer's disease: protector or promoter?. Bratisl. Lek. Listy. 107 (2006) 374-383
132. Fiala M., Cribbs D.H., Rosenthal M., and Bernard G. Phagocytosis of amyloid-β and inflammation: two faces of innate immunity in Alzheimer's disease. J. Alzheimers Dis. 11 (2007) 457-463
133. Papadopoulos V., Amri H., Li H., Yao Z., Brown R.C., Vidic B., and Culty M. Structure, function and regulation of the mitochondrial peripheral-type benzodiazepine receptor. Therapie 56 (2001) 549-556
134. Casellas P., Galiegue S., and Basile A.S. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem. Int. 40 (2002) 475-486
135. Papadopoulos V., Baraldi M., Guilarte T.R., Knudsen T.B., Lacapère J.J., Lindemann P., Norenberg M.D., Nutt D., Weizman A., Zhang M.R., and Gavish M. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 27 (2006) 402-409
136. Veenman L., Papadopoulos V., and Gavish M. Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr. Pharm. Des. 13 (2007) 2385-2405
137. Benavides J., Fage D., Carter C., and Scatton B. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage. Brain Res. 421 (1987) 167-172
138. Dubois A., Benavides J., Peny B., Duverger D., Fage D., Gotti B., MacKenzie E.T., and Scatton B. Imaging of primary and remote ischaemic and excitotoxic brain lesions. An autoradiographic study of peripheral type benzodiazepine binding sites in the rat and cat. Brain Res. 445 (1988) 77-90
139. Bourdiol F., Toulmond S., Serrano A., Benavides J., and Scatton B. Increase in omega 3 (peripheral type benzodiazepine) binding sites in the rat cortex and striatum after local injection of interleukin-1, tumour necrosis factor-α and lipopolysaccharide. Brain Res. 543 (1991) 194-200
140. 3H]PK 11195 binding in rat cerebral cortex following a local ischaemic lesion. J. Cereb. Blood Flow Metab. 11 (1991) 314-322
141. Guilarte T.R., Kuhlmann A.C., O'Callaghan J.P., and Miceli R.C. Enhanced expression of peripheral benzodiazepine receptors in trimethyltin-exposed rat brain: a biomarker of neurotoxicity. Neurotoxicology 16 (1995) 441-450
142. Stephenson D.T., Schober D.A., Smalstig E.B., Mincy R.E., Gehlert D.R., and Clemens J.A. Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J. Neurosci. 15 (1995) 5263-5274
143. 3H]PK11195 binding to activated microglia. J. Neurocytol. 26 (1997) 77-82
144. Rao R.V.L., Dogan A., Bowen K.K., and Dempsey R.J. Traumatic brain injury leads to increased expression of peripheral-type benzodiazepine receptors, neuronal death, and activation of astrocytes and microglia in rat thalamus. Exp. Neurol. 161 (2000) 102-114
145. Chen M.K., Baidoo K., Verina T., and Guilarte T.R. Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. Brain 127 (2004) 1379-1392
146. Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., Jones T., and Banati R.B. In-vivo measurement of activated microglia in dementia. Lancet 358 (2001) 461-467
147. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., and Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57 (2005) 168-175
148. 11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21 (2006) 404-412
149. 11C]PIB-PET study. Neurobiol. Dis. 32 (2008) 412-419
150. Okello A., Edison P., Archer H.A., Turkheimer F.E., Kennedy J., Bullock R., Walker Z., Kennedy A., Fox N., Rossor M., and Brooks D.J. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 72 (2009) 56-62
151. Wiley C.A., Lopresti B.J., Venneti S., Price J., Klunk W.E., DeKosky S.T., and Mathis C.A. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch. Neurol. 66 (2009) 60-67
152. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., and Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci. 15 (2002) 991-998
153. Venneti S., Lopresti B.J., Wang G., Hamilton R.L., Mathis C.A., Klunk K.W., Apte U.M., and Wiley C.A. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol. Aging 30 (2009) 1217-1226
154. 11C]DAA1106 for PET: an imaging tool for glial cells in the brain. Synapse 52 (2004) 283-291
155. 18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain. J. Med. Chem. 247 (2004) 2228-2235
156. Maeda J., Higuchi M., Inaji M., Ji B., Haneda E., Okauchi T., Zhang M.R., Suzuki K., and Suhara T. Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res. 1157 (2007) 100-111
157. Venneti S., Lopresti B.J., Wang G., Slagel S.L., Mason N.S., Mathis C.A., Fischer M.L., Larsen N.J., Mortimer A.D., Hastings T.G., Smith A.D., Zigmond M.J., Suhara T., Higuchi M., and Wiley C.A. A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation. J. Neurochem. 102 (2007) 2118-2131
158. Ji B., Maeda J., Sawada M., Ono M., Okauchi T., Inaji M., Zhang M.R., Suzuki K., Ando K., Staufenbiel M., Trojanowski J.Q., Lee V.M., Higuchi M., and Suhara T. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J. Neurosci. 28 (2008) 12255-12267
159. 11C-AC-5216: a novel PET ligand for peripheral benzodiazepine receptors in the primate brain. J. Nucl. Med. 48 (2007) 1853-1861
160. 18F]FEDAC: two novel positron emission tomography ligands for peripheral-type benzodiazepine receptor in the brain. Bioorg. Med. Chem. Lett. 19 (2009) 1707-1710
161. 18F-FEDAA1106 binding to peripheral benzodiazepine receptors in living human brain. J. Nucl. Med. 47 (2006) 43-50
162. 11C]DAA1106. J. Cereb. Blood Flow Metab. 27 (2007) 173-184
163. 11C-AC-5216. J. Nucl. Med. 50 (2009) 1095-1101
164. 11C]DAA1106. Biol. Psychiatry 64 (2008) 835-841
165. Sw transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56 (1997) 965-973
166. Calhoun M.E., Wiederhold K.H., Abramowski D., Phinney A.L., Probst A., Sturchler-Pierrat C., Staufenbiel M., Sommer B., and Jucker M. Neuron loss in APP transgenic mice. Nature 395 (1998) 755-756
167. Bondolfi L., Calhoun M., Ermini F., Kuhn H.G., Wiederhold K.H., Walker L., Staufenbiel M., and Jucker M. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J. Neurosci. 22 (2002) 515-522
168. Phinney A.L., Deller T., Stalder M., Calhoun M.E., Frotscher M., Sommer B., Staufenbiel M., and Jucker M. Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice. J. Neurosci. 19 (1999) 8552-8559
169. Marzo I., Brenner C., and Kroemer G. The central role of the mitochondrial megachannel in apoptosis: evidence obtained with intact cells, isolated mitochondria, and purified protein complexes. Biomed. Pharmacother. 52 (1998) 248-251
170. m) in apoptosis; an update. Apoptosis 8 (2003) 115-128
171. Rodriguez-Enriquez S., He L., and Lemasters J.J. Role of mitochondrial permeability transition pores in mitochondrial autophagy. Int. J. Biochem. Cell Biol. 36 (2004) 2463-2472
172. Zorov D.B., Juhaszova M., and Sollott S.J. Mitochondrial ROS-induced ROS release: an update and review. Biochim. Biophys. Acta 1757 (2006) 509-517
173. Brady N.R., Hamacher-Brady A., Westerhoff H.V., and Gottlieb R.A. A wave of reactive oxygen species (ROS)-induced ROS release in a sea of excitable mitochondria. Antioxid. Redox Signal. 8 (2006) 1651-1665
174. Lacapere J.J., and Papadopoulos V. Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis. Steroids 68 (2003) 569-585
175. Ansseau M., von Frenckell R., Cerfontaine J.L., and Papart P. Pilot study of PK 11195, a selective ligand for the peripheral-type benzodiazepine binding sites, in inpatients with anxious or depressive symptomatology. Pharmacopsychiatry 24 (1991) 8-12
176. Okuyama S., Chaki S., Yoshikawa R., Ogawa S., Suzuki Y., Okubo T., Nakazato A., Nagamine M., and Tomisawa K. Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA1097 and DAA1106. Life Sci. 64 (1999) 1455-1464
177. Kita A., Kohayakawa H., Kinoshita T., Ochi Y., Nakamichi K., Kurumiya S., Furukawa K., and Oka M. Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand. Br. J. Pharmacol. 142 (2004) 1059-1072
178. Rupprecht R., Rammes G., Eser D., Baghai T.C., Schüle C., Nothdurfter C., Troxler T., Gentsch C., Kalkman H.O., Chaperon F., Uzunov V., McAllister K.H., Bertaina-Anglade V., La Rochelle C.D., Tuerck D., Floesser A., Kiese B., Schumacher M., Landgraf R., Holsboer F., and Kucher K. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325 (2009) 490-493
179. Mark R.J., Hensley K., Butterfield D.A., and Mattson M.P. Amyloid β-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death. J. Neurosci. 15 (1995) 6239-6249
180. Mattson M.P. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell. Biol. 1 (2001) 121-129
181. Kusakawa G., Saito T., Onuki R., Ishiguro K., Kishimoto T., and Hisanaga S. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J. Biol. Chem. 275 (2000) 17166-17172
182. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., and Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405 (2000) 360-364
183. Saito K., Elce J.S., Hamos J.E., and Nixon R.A. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 2628-2632
184. Higuchi M., Iwata N., and Saido T.C. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. Biochim. Biophys. Acta 1751 (2005) 60-67
185. Higuchi M., Tomioka M., Takano J., Shirotani K., Iwata N., Masumoto H., Maki M., Itohara S., and Saido T.C. Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors. J. Biol. Chem. 280 (2005) 15229-15237
186. Takano J., Tomioka M., Tsubuki S., Higuchi M., Iwata N., Itohara S., Maki M., and Saido T.C. Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. J. Biol. Chem. 280 (2005) 16175-16184
187. Trinchese F., Fa' M., Liu S., Zhang H., Hidalgo A., Schmidt S.D., Yamaguchi H., Yoshii N., Mathews P.M., Nixon R.A., and Arancio O. Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J. Clin. Invest. 118 (2008) 2796-2807
188. Wang K.K.W., and Yuen P.W. Calpain substrates, assay methods, regulation, and its inhibitory agents. In: Wang K.K.W., and Yuen P.W. (Eds). Calpain: Pharmacology and Toxicology of Calcium-Dependent Protease (1999), Taylor & Francis, Philadelphia 77-101
189. Hanna R.A., Campbell R.L., and Davies P.L. Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin. Nature 456 (2008) 409-413
190. Zhang B., Higuchi M., Yoshiyama Y., Ishihara T., Forman M.S., Martinez D., Joyce S., Trojanowski J.Q., and Lee V.M. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J. Neurosci. 24 (2004) 4657-4667
191. Du H., Guo L., Fang F., Chen D., Sosunov A.A., McKhann G.M., Yan Y., Wang C., Zhang H., Molkentin J.D., Gunn-Moore F.J., Vonsattel J.P., Arancio O., Chen J.X., and Yan S.D. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 14 (2008) 1097-1105
192. Bratton S.B., and Cohen G.M. Apoptotic death sensor: an organelle's alter ego?. Trends Pharmacol. Sci. 22 (2001) 306-315
193. 2+ and oxidant stress. Eur. J. Biochem. 238 (1996) 166-172
194. Green K.N., Smith I.F., and Laferla F.M. Role of calcium in the pathogenesis of Alzheimer's disease and transgenic models. Subcell. Biochem. 45 (2007) 507-521
195. Koutsilieri E., and Riederer P. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease. Parkinsonism Relat. Disord. 13 (2007) S329-S331
196. Monaghan D.T., and Jane D.E. Pharmacology of NMDA receptors. In: VanDongen A.M. (Ed). Biology of the NMDA Receptor (2008), CRC Press, New York 257-328
197. Haradahira T., Zhang M., Maeda J., Okauchi T., Kawabe K., Kida T., Suzuki K., and Suhara T. A strategy for increasing the brain uptake of a radioligand in animals: use of a drug that inhibits plasma protein binding. Nucl. Med. Biol. 27 (2000) 357-360
198. Haradahira T., Zhang M.R., Maeda J., Okauchi T., Kida T., Kawabe K., Sasaki S., Suhara T., and Suzuki K. A prodrug of NMDA/glycine site antagonist, L-703, 717, with improved BBB permeability: 4-acetoxy derivative and its positron-emitter labeled analog. Chem. Pharm. Bull. 49 (2001) 147-150
199. 11C] methoxybenzyl) phenyl]-2(1H)-quinolone (AcL703) with positron emission tomography. Synapse 61 (2007) 795-800
200. Raina P., Santaguida P., Ismaila A., Patterson C., Cowan D., Levine M., Booker L., and Oremus M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Int. Med. 148 (2008) 379-397
201. Bronfman F.C., Moechars D., and Van Leuven F. Acetylcholinesterase-positive fiber deafferentation and cell shrinkage in the septohippocampal pathway of aged amyloid precursor protein london mutant transgenic mice. Neurobiol. Dis. 7 (2000) 152-168
202. Ohno M., Sametsky E.A., Younkin L.H., Oakley H., Younkin S.G., Citron M., Vassar R., and Disterhoft J.F. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41 (2004) 27-33
203. Van Dam D., Marescau B., Engelborghs S., Cremers T., Mulder J., Staufenbiel M., and De Deyn P.P. Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. Neurochem. Int. 46 (2005) 409-422
204. Bell K.F., Ducatenzeiler A., Ribeiro-da-Silva A., Duff K., Bennett D.A., and Cuello A.C. The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol. Aging 27 (2006) 1644-1657
205. Iyo M., Namba H., Fukushi K., Shinotoh H., Nagatsuka S., Suhara T., Sudo Y., Suzuki K., and Irie T. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 349 (2007) 1805-1809
206. Kuhl D.E., Koeppe R.A., Minoshima S., Snyder S.E., Ficaro E.P., Foster N.L., Frey K.A., and Kilbourn M.R. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 52 (1999) 691-699
207. Okamura N., Funaki Y., Tashiro M., Kato M., Ishikawa Y., Maruyama M., Ishikawa H., Meguro K., Iwata R., and Yanai K. In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease. Br. J. Pharmacol. 65 (2008) 472-479
208. Namba H., Fukushi K., Nagatsuka S., Iyo M., Shinotoh H., Tanada S., and Irie T. Positron emission tomography: quantitative measurement of brain acetylcholinesterase activity using radiolabeled substrates. Methods 27 (2002) 242-250
209. Kepe V., Barrio J.R., Huang S.C., Siddarth P., Shoghi-Jadid K., Cole G.M., Satyamurthy N., Cummings J.L., Small G.W., and Phelps M.E. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 702-707
210. Truchot L., Costes S.N., Zimmer L., Laurent B., Le Bars D., Thomas-Antérion C., Croisile B., Mercier B., Hermier M., Vighetto A., and Krolak-Salmon P. Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment. Neurology 69 (2007) 1012-1017
211. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 20 (2000) 423-451
212. 11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J. Neurochem. 97 (2006) 1089-1103
213. 11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology 33 (2008) 279-289
214. 11C]MNPA. Synapse 62 (2008) 756-763
215. Tokunaga M., Seneca N., Shin R.M., Maeda J., Obayashi S., Okauchi T., Nagai Y., Zhang M.R., Nakao R., Ito H., Innis R.B., Halldin C., Suzuki K., Higuchi M., and Suhara T. Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system. J. Neurosci. 29 (2009) 1887-1896
216. Matthews B., Siemers E.R., and Mozley P.D. Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease. Am. J. Geriatr. Psychiatry 11 (2003) 146-159
217. Magistretti P.J., and Pellerin L. Cellular mechanisms of brain energy metabolism. Relevance to functional brain imaging and to neurodegenerative disorders. Ann. N. Y. Acad. Sci. 777 (1996) 380-387
218. Leow A.D., Yanovsky I., Parikshak N., Hua X., Lee S., Toga A.W., Jack Jr. C.R., Bernstein M.A., Britson P.J., Gunter J.L., Ward C.P., Borowski B., Shaw L.M., Trojanowski J.Q., Fleisher A.S., Harvey D., Kornak J., Schuff N., Alexander G.E., Weiner M.W., Thompson P.M., and Alzheimer's Disease Neuroimaging Initiative. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage 45 (2009) 645-655
219. Beuf O. High-resolution MRI techniques for studies in small-animal models. Methods Mol. Med. 101 (2004) 219-229
220. Tai Y.C., Ruangma A., Rowland D., Siegel S., Newport D.F., Chow P.L., and Laforest R. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J. Nucl. Med. 46 (2005) 455-463
221. 14C-DG autoradiography. J. Nucl. Med. 45 (2004) 1398-1405